Susquehanna International Group’s Orchestra BioMed OBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$414K Sell
97,521
-57,609
-37% -$245K ﹤0.01% 10128
2025
Q4
$644K Buy
155,130
+57,025
+58% +$230K ﹤0.01% 8220
2025
Q3
$243K Sell
98,105
-20,453
-17% -$56.4K ﹤0.01% 10576
2025
Q2
$318K Buy
118,558
+85,570
+259% +$250K ﹤0.01% 10205
2025
Q1
$141K Buy
32,988
+20,819
+171% +$104K ﹤0.01% 11278
2024
Q4
$48.7K Buy
+12,169
New +$65.4K ﹤0.01% 11689
2023
Q4
Sell
-12,647
Closed -$110K 13019
2023
Q3
$110K Buy
+12,647
New +$85K ﹤0.01% 10839

Other funds holding OBIO

Susquehanna International Group's OBIO Position: Q1 2026 in Review

Susquehanna International Group reduced its Orchestra BioMed (OBIO) stake by 37% in Q1 2026, selling an estimated $245K and leaving 97,521 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #10128.

Susquehanna International Group first reported a position in OBIO in Q3 2023 and has held it in 7 quarters since. The position peaked at $644K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Susquehanna International Group held 97,521 shares of Orchestra BioMed worth $414K as of Q1 2026.
  • Susquehanna International Group sold 57,609 Orchestra BioMed shares in Q1 2026, an estimated $245K.
  • Orchestra BioMed made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10128 holding.
  • Susquehanna International Group first reported a position in Orchestra BioMed in Q3 2023 and has held it in 7 quarters since.
  • Susquehanna International Group's Orchestra BioMed position peaked at $644K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.